Abstract
Myofascial pain is an important yet under recognised component of cancer pain. It has a prevalence of between 11.9 and 44.8% in cancer patients. Treatments for myofascial pain reduce the prevalence of myofascial trigger points therefore decreasing pain and improving range of motion. Pridinol is a nonbenzodiazepine antispasmodic licenced for the treatment of central and peripheral muscle spasms in adults. This paper describes two case histories where patients with myofascial pain were successfully treated with pridinol. These cases highlight the importance of treating myofascial pain and the potential of pridinol to treat cancer-related myofascial pain.
Subject
Medical–Surgical Nursing,Oncology (nursing),General Medicine,Medicine (miscellaneous)
Reference5 articles.
1. Myofascial component of cancer pain review;Kalichman;J Bodyw Mov Ther,2019
2. Diagnosis of Myofascial Pain Syndrome
3. Interventions for myofascial pain syndrome in cancer pain: recent advances: why, when, where and how;Thottungal;Curr Opin Support Palliat Care,2019
4. Efficacy and safety/tolerability of pridinol: a meta-analysis of double-blind, randomized, placebo-controlled trials in adult patients with muscle pain;Überall;Curr Med Res Opin,2022
5. Efficacy and tolerability of the antispasmodic, pridinol, in patients with muscle-pain – results of primepain, a retrospective analysis of open-label real-world data provided by the German pain E-registry;Überall;Curr Med Res Opin,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献